JCHOR

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

EndNote Style
Index
Case Report
Primary spinal extramedullary diffuse large B–cell lymphoma presenting with initial spinal cord compression: A case report
Extranodal lymphomas, by definition, can involve any organ or tissue. Brain parenchyma, spinal cord, eyes, cranial nerves, and meninx are extranodal regions that show involvement at much lower rates. Primary central nervous system (CNS) lymphomas comprise 4% of all brain tumors and 4–6% of extranodal lymphomas. It is quite rare for lymphoma patients to present to the hospital with symptoms and findings associated with spinal cord compression as the initial presentation. This condition can lead to irreversible autonomic dysfunction, and motor and sensory loss. Here, we present a rare primary spinal intradural extramedullary diffuse large B–cell lymphoma (DLBCL) case who presented with acute neurological symptoms and no findings of cerebral involvement or involvement at any other site. MRI was performed for the spinal region. The surgical procedure was performed for the detected mass. Immunohistochemical staining of the excised mass was performed. In the surgical operation, the mass showed partial invasion of the vertebral bone and the surrounding muscle. Considering the rapid progression of the neurological deficit, surgical resection was performed primarily for spinal decompression. Subsequently, 6 courses of R–CHOP chemotherapy regimen were given for the residual tissue, and radiotherapy was administered to the involved region. Timely and effective treatment achieved a complete recovery of motor and sensory function. The patient remains in complete remission without clinical or radiological relapse under follow-up after nearly 4 years. Isolated MS is a rare hematologic neoplasia comprised of immature granulocytic cells. Although it can be detected in any part of the body, hepatobiliary, and particularly, pancreatic involvement is much less frequent. The optimal treatment of the disease is not elucidated due to the lack of relevant data and large prospective studies in the literature. The most recommended treatments are the systemic chemotherapies used in AML remission induction treatment. The authors think that alloHSCT must be considered after the induction of remission in MS, as it offers an advantage in terms of overall survival and leukemia–free survival.


1. Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012;25(1):119-130. doi:10.1016/j.beha.2011.12.001
2. Dogan A, Doğan NY, Erkurt MA, Ekinci Ö, Kuku İ, Kaya E. Clinical and pathological characteristics of patients with non-Hodgkin lymphoma cases in Eastern Turkey. Cukurova Med J. 2020;45(2):533-540. doi:10.17826/cumj.672199
3. Thieblemont C, Gomes Da Silva M, Leppä S, et al. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Hemasphere. 2025;9(9):e70207. doi:10.1002/hem3.70207
4. Vinnicombe S, Reznek R. Extranodal manifestations of lymphoma. Imaging. 1999;11(4):240-268. doi:10.1259/img.11.4.110240
5. Mak KS, Lee LK, Mak RH, et al. Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006. Int J Radiat Oncol Biol Phys. 2011;80(3):824-831. doi:10.1016/j.ijrobp.2010.03.022
6. Liu S-Z, Zhou X, Song A, Huo Z, Wang Y-P, Liu Y. Primary spinal epidural non-Hodgkin’s lymphoma causing complete paralysis. QJM. 2018;111(11):813-814. doi:10.1093/qjmed/hcy151
7. Nakamizo T, Inoue H, Udaka F, et al. Magnetic resonance imaging of primary spinal intramedullary lymphoma. J Neuroimaging. 2002;12(2): 183-186. doi:10.1111/j.1552-6569.2002.tb00118.x
8. Ferreri A, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513-1520. doi:10.1212/wnl.58.10.1513
9. Shu Y, Wang A, Yi L, Xu X, Yang W. Primary spinal epidural diffuse large B-cell lymphoma with paraplegia as the first manifestation: a case report. Onco Targets Ther. 2019;12:6497-6501. doi:10.2147/OTT.S217703
10. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
11. Yaman S, Bozan E, Başcı S. Diffuse large B-cell lymphoma. In: Rezaei N, editor. Comprehensive Hematology and Stem Cell Research (First Edition). Oxford: Elsevier; 2024.
12. Pinar IE, Ozkocaman V, Ersal T, et al. Comparison of International Prognostic Indices and validation study for patients with diffuse large B-cell lymphoma in the rituximab era. UHOD. 2023;33(2):57-65. doi:10.4999/uhod.236953
13. Tang Y, Yang X, Xiao J, et al. Clinical outcomes of treatment for spinal cord compression due to primary non-Hodgkin lymphoma. Spine J. 2013;13(6):641-650. doi:10.1016/j.spinee.2012.11.054
14. Peng X, Wan Y, Chen Y, et al. Primary non-Hodgkin’s lymphoma of the spine with neurologic compression treated by radiotherapy and chemotherapy alone or combined with surgical decompression. Oncol Rep. 2009;21(5):1269-1275. doi:10.3892/or_00000350
15. Perry JR, Deodhare SS, Bilbao JM, Murray D, Muller P. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery. 1993;32(2):157-162. doi:10.1227/00006123-199302000-00001
Volume 4, Issue 3, 2026
Page : 116-119
_Footer